All In Biotech

Drug Trial Radar · NCT03195699

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced Cancers

Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Nov 15, 2017

Primary completion

Jun 24, 2024

Study completion Jun 24, 2024

Sponsor

Sponsor type
Industry
Collaborators
M.D. Anderson Cancer Center
First posted
Jun 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Many patients have cancers that have increased activity of a protein called STAT3 that contributes critically to the development and growth of their cancer. Despite our knowledge of STAT3's importance to cancer, scientists and doctors have not developed a drug that targets it and that patients can take to treat their cancer more effectively than treatments that are now available. Tvardi Therapeutics, Incorporated has developed a compound, TTI-101, which can be given by mouth and acts as a direct inhibitor of STAT3. Administration of TTI-101 to mice demonstrated that it blocked growth of cancers of the breast, head and neck, lung, and liver and it was safe when administered at high doses to mice, rats, and dogs. In this application, Tvardi is proposing to further develop TTI-101 for treatment of solid tumors for which the prognosis is dismal. The investigators will determine how safe it is when administered to patients with cancer, determine whether an adequate dose can be administered to patients with cancer that will block STAT3 in their cancer, and determine whether treatment with TTI-101 leads to reduced growth of their cancer.

Conditions

  • Breast Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Non Small Cell Lung Cancer
  • Hepatocellular Cancer
  • Colorectal Cancer
  • Gastric Adenocarcinoma
  • Melanoma
  • Advanced Cancer

Interventions

  • TTI-101Drug

    Oral capsule

  • TTI-101Drug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose of TTI-101Time frame: 28 days
  2. Pharmacokinetics - CmaxTime frame: 18 months
  3. Pharmacokinetics - TmaxTime frame: 18 months
  4. Pharmacokinetics - AUC(0-t)Time frame: 18 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Mays Cancer Center at University of Texas Health Science Center SA

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.